NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 3, 2015, Pages 301-309

  Corey, K E ^a   Vuppalanchi, R ^b   Wilson, L A ^c   Cummings, O W ^b   Chalasani, N ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; HDL-TRIGLYCERIDE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DIET RESTRICTION; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; CONTROLLED STUDY; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK; THIAZOLIDINEDIONES; TRIGLYCERIDES; VITAMIN E;

EID: 84920704622     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13035     Document Type: Article

References (31)

1. Dunn W, Xu R, Wingard DL, et al,. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-71.
2. Ekstedt M, Franzen LE, Mathiesen UL, et al,. Long-term follow-up of patients with nafld and elevated liver enzymes. Hepatology 2006; 44: 865-73.
3. Soderberg C, Stal P, Askling J, et al,. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
4. Targher G, Bertolini L, Rodella S, et al,. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.
5. Ruhl CE, Everhart JE,. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004; 8: 501-19, vii.
6. DeFilippis AP, Blaha MJ, Martin SS, et al,. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis 2013; 227: 429-36.
7. Toledo FG, Sniderman AD, Kelley DE,. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006; 29: 1845-50.
8. Speliotes EK, Massaro JM, Hoffmann U, et al,. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the framingham heart study. Hepatology 2010; 51: 1979-87.
9. Miller M, Stone NJ, Ballantyne C, et al,. Triglycerides and cardiovascular disease: a scientific statement from the american heart association. Circulation 2011; 123: 2292-333.
10. Hanak V, Munoz J, Teague J, Stanley A Jr, Bittner V,. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype b. Am J Cardiol 2004; 94: 219-22.
11. Drexel H, Aczel S, Marte T, et al,. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated ldl cholesterol or by decreased hdl cholesterol? Diabetes Care 2005; 28: 101-7.
12. Assmann G, Schulte H,. The importance of triglycerides: results from the prospective cardiovascular munster (procam) study. Eur J Epidemiol 1992; 8 (Suppl. 1): 99-103.
13. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE,. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96: 2520-5.
14. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F,. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001; 161: 361-6.
15. Bittner V, Johnson BD, Zineh I, et al,. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the women's ischemia syndrome evaluation (wise). Am Heart J 2009; 157: 548-55.
16. Corey KE, Lai M, Gelrud L, et al,. Non-high density lipoprotein cholesterol as a biomarker for non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2012; 10: 651-56.
17. Robinson JG, Wang S, Smith BJ, Jacobson TA,. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009; 53: 316-22.
18. Sanyal AJ, Chalasani N, Kowdley KV, et al,. Pioglitazone, vitamin e, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
19. Kleiner DE, Brunt EM, Van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
20. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB,. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
21. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P,. The framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32: 645-50.
22. Goldberg RB, Kendall DM, Deeg MA, et al,. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-54.
23. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ,. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-9.
24. Gotto AM Jr, Whitney E, Stein EA, et al,. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the air force/texas coronary atherosclerosis prevention study (afcaps/texcaps). Circulation 2000; 101: 477-84.
25. Brewer HB Jr,. Increasing hdl cholesterol levels. N Engl J Med 2004; 350: 1491-4.
26. Ashen MD, Blumenthal RS,. Clinical practice. Low hdl cholesterol levels. N Engl J Med 2005; 353: 1252-60.
27. Arsenault BJ, Rana JS, Stroes ES, et al,. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009; 55: 35-41.
28. Sarwar N, Danesh J, Eiriksdottir G, et al,. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007; 115: 450-8.
29. Wurch T, Junquero D, Delhon A, Pauwels J,. Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 133-40.
30. Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA,. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-5.
31. Laurin J, Lindor KD, Crippin JS, et al,. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.